Premium
Acquired cholesteatoma epithelial hyperproliferation: Roles of cell proliferation signal pathways
Author(s) -
Xie Shumin,
Xiang Yuyan,
Wang Xiaoli,
Ren Hongmiao,
Yin Tuanfang,
Ren Jihao,
Liu Wei
Publication year - 2016
Publication title -
the laryngoscope
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.181
H-Index - 148
eISSN - 1531-4995
pISSN - 0023-852X
DOI - 10.1002/lary.25834
Subject(s) - cholesteatoma , signal transduction , cell growth , medicine , keratinocyte growth factor , cancer research , stat protein , microbiology and biotechnology , epidermal growth factor , growth factor , receptor , biology , stat3 , surgery , biochemistry
Objectives/Hypothesis To review the recent cell proliferation signal pathways in the etiopathogenesis of acquired middle ear cholesteatoma. Data Sources PubMed (to September 2015). Review Methods Articles about cell proliferation signal pathways in the etiopathogenesis of acquired cholesteatoma and treatment advances were searched in the PubMed database, from which 73 were included in this review. Results The exact underlying cellular and molecular mechanism of acquired cholesteatoma still remains unknown. Recent research tends to regard the proliferation of cholesteatoma epithelial cells as the mechanism of cholesteatoma pathogenesis. Cell proliferation signal pathways including epidermal growth factor receptor/phosphoinositide 3‐kinase/protein kinase B signal pathway, mitogen‐activated protein kinase signal pathway, interleukin‐6/signal transducer and activator of transcription 3 signal pathway, inhibitor of DNA binding/differentiation‐1/nuclear factor‐κB/cyclinD1 signal pathway, microRNA‐mediated proliferation signal pathway, and keratinocyte growth factor/keratinocyte growth factor receptor signal pathway have been proven to play important roles in acquired middle ear cholesteatoma. Conclusions This review outlines the main biological properties of certain cell proliferation signal pathways, aiming to facilitate the development of potential therapeutic targets for intratympanic drug therapy for the nonsurgical or complementary treatment of cholesteatoma. Level of Evidence NA Laryngoscope , 126:1923–1930, 2016